As filed with the Securities and Exchange Commission on March 20, 2025
Registration No. 333-[xxxx]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
BIOAGE LABS, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
47-4721157 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
incorporation or organization) |
|
Identification Number) |
1445A South 50th Street
Richmond, California 94804
(510) 806-1445
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
2024 Equity Incentive Plan
2024 Employee Stock Purchase Plan
(Full title of the plans)
Kristen Fortney, Ph.D.
Chief Executive Officer and President
BioAge Labs, Inc.
1445A South 50th Street
Richmond, California 94804
(510) 806-1445
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Please send copies of all communications to:
Matthew Rossiter, Esq.
Robert A. Freedman, Esq.
Julia Forbess, Esq.
Fenwick & West LLP
555 California Street, 12th Floor
San Francisco, California 94104
(415) 875-2300
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|||
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|||
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
Pursuant to General Instruction E of Form S-8, BioAge Labs, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register (a) 1,792,501 additional shares of the Registrant’s common stock, par value $0.00001 per share (“common stock”) under the Registrant’s 2024 Equity Incentive Plan and (b) 358,500 additional shares of the Registrant’s common stock under the Registrant’s 2024 Employee Stock Purchase Plan, pursuant to the provisions in those plans providing for an automatic annual increase in the number of shares reserved for issuance under such plans on January 1, 2025. This Registration Statement hereby incorporates by reference the contents of the Registrant’s previous registration statement on Form S-8 filed with the Commission on September 26, 2024 (Registration No. 333-282352) to the extent not superseded hereby.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information called for by Part I of Form S-8 is omitted from this Registration Statement and has been or will be sent or given to participating service providers in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:
All documents filed by the Registrant with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished an note filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.
Item 5. Interests of Named Experts and Counsel
As of the date of this registration statement, individuals and entities associated with Fenwick & West LLP beneficially own an aggregate of 16,653 shares of the Registrant’s common stock.
Item 8. Exhibits
The following exhibits are filed herewith:
Exhibit |
|
Incorporated by Reference |
||||
Number |
Exhibit Description |
Form |
File No. |
Exhibit |
Filing Date |
Filed Herewith |
3.1 |
10-Q |
001-42279 |
3.1 |
11/7/2024 |
|
|
3.2 |
10-Q |
001-42279 |
3.2 |
11/7/2024 |
|
|
4.1 |
S-1/A |
333-281901 |
4.1 |
09/03/2024 |
|
|
5.1 |
|
|
|
|
X |
|
23.1 |
|
|
|
|
X |
|
23.2 |
|
|
|
|
X |
|
24.1 |
Power of Attorney (included on the signature page to this Registration Statement) |
|
|
|
|
X |
99.1 |
2024 Equity Incentive Plan, and forms of award agreements thereunder |
10-K |
001-42279 |
10.2 |
03/20/2025 |
|
99.2 |
2024 Employee Stock Purchase Plan, and forms of award agreements thereunder |
S-1/A |
33-281901 |
10.4 |
09/18/2024 |
|
107 |
|
|
|
|
X |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Richmond, State of California, on this 20th day of March, 2025.
|
|
|
BIOAGE LABS, INC. |
||
|
|
|
By: |
|
/s/ Kristen Fortney, Ph.D. |
|
|
Kristen Fortney, Ph.D. |
|
|
Chief Executive Officer and President |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kristen Fortney, Ph.D. and Dov Goldstein, M.D., and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the date indicated.
|
|
|
|
|
Name |
|
Title |
|
Date |
/s/ Kristen Fortney Kristen Fortney, Ph.D. |
|
Chief Executive Officer, President and Director (Principal Executive Officer) |
|
March 20, 2025 |
|
|
|
||
/s/ Dov Goldstein Dov Goldstein, M.D. |
|
Chief Financial Officer (Principal Financial Officer) |
|
March 20, 2025 |
|
|
|
||
/s/ Shane Barton Shane Barton |
|
Senior Vice President of Finance (Principal Accounting Officer) |
|
March 20, 2025 |
|
|
|
||
/s/ Jean-Pierre Garnier Jean-Pierre Garnier, Ph.D. |
|
Chair of the Board of Directors |
|
March 20, 2025 |
|
|
|
||
/s/ Michael Davidson Michael Davidson, M.D. |
|
Director |
|
March 20, 2025 |
|
|
|
||
/s/ Patrick Enright Patrick Enright |
|
Director |
|
March 20, 2025 |
|
|
|
||
/s/ James Healy James Healy, M.D., Ph.D. |
|
Director |
|
March 20, 2025 |
|
|
|
|
|
|
|
|
||
/s/ Rekha Hemrajani Rekha Hemrajani |
|
Director |
|
March 20, 2025 |
|
|
|
||
/s/ Eric Morgen Eric Morgen, M.D. |
|
Director |
|
March 20, 2025 |
|
|
|
||
/s/ Vijay Pande Vijay Pande, Ph.D. |
|
Director |
|
March 20, 2025 |